Profound Medical Cuts Losses by 39% as Revenue Growth Accelerates
Event summary
- Profound Medical reported a 39% year-over-year improvement in net loss to $9.5 million, driven by a 16% reduction in operating expenses.
- $2.5 million of new purchase orders were recognized as revenue in Q2, with an additional $3.1 million shipped in July and deferred to Q3 due to logistics issues.
- Reimbursement coverage expanded by 18.3 million lives, including the first employer-owned health plans listing the TULSA Procedure as a covered service.
- TULSA-PRO installed base grew to 84 systems, with a $70 million qualified sales pipeline for TULSA-PRO and Sonalleve.
- Gross margin expanded to 78% in Q2 from 73% year-over-year.
The big picture
Profound Medical's strategic focus on cost reduction and reimbursement expansion positions it to capitalize on growing clinical validation of its TULSA Procedure. The company's ability to sustain operating leverage while scaling commercial adoption will be critical as it competes in the interventional MRI space. With $38.3 million in cash reserves, Profound has runway to execute its growth strategy, but must demonstrate consistent revenue growth to justify its valuation.
What we're watching
- Revenue Recognition Timing
- The impact of shipment timing on revenue recognition and whether the deferred $3.1 million will sustain Q3 growth momentum.
- Commercial Pipeline Execution
- How Profound Medical converts its $70 million sales pipeline into actual revenue, given historical conversion rates.
- Reimbursement Expansion
- The pace at which payer coverage expands beyond Medicaid and managed Medicaid programs to include commercial insurers.